期刊
ARTHRITIS & RHEUMATOLOGY
卷 73, 期 2, 页码 255-264出版社
WILEY
DOI: 10.1002/art.41485
关键词
-
类别
资金
- French CRC 2017 Ministere de la Sante [17068]
- Agence Nationale de la Recherche [JCJC SVSE1 2011 BASILE, JCJC CE17 2015 BATTL]
- Ministere de la Recherche, Association Nationale de la Recherche et de la Technologie-Conventions Industrielles de Formation par la Recherche
- DHU Fire (Bourse Emergence 4)
- Fondation pour la Recherche Medicale [DEA20170638077]
Research suggests that BAFF neutralization may have a potential protective effect on cardiovascular disease in patients with systemic lupus erythematosus, but this may be influenced by factors such as body mass index.
Objective Cardiovascular disease (CVD) is the leading cause of death in systemic lupus erythematosus (SLE). B cells play a key role in the pathogenesis of lupus, and anti-BAFF therapy has been approved for use in SLE. Since mature B cells also promote atherosclerosis, we undertook this study to evaluate, in a mouse model and in SLE patients, whether BAFF neutralization has an atheroprotective effect in SLE. Methods The effect of BAFF on atherosclerosis associated with lupus was investigated in the atherosclerosis/lupus-prone apolipoprotein E-knockout D227K mouse model and in a cohort of SLE patients. Mice were treated with a blocking anti-BAFF monoclonal antibody (mAb), while fed a standard chow diet. Carotid plaque and carotid intima-media thickness were assessed by ultrasound at baseline and during follow-up in SLE patients who were asymptomatic for CVD. Results Anti-BAFF mAb in ApoE(-/-) D227K mice induced B cell depletion, efficiently treated lupus, and improved atherosclerosis lesions (21% decrease; P = 0.007) in mice with low plasma cholesterol levels but worsened the lesions (17% increase; P = 0.06) in mice with high cholesterol levels. The atheroprotective effect of the BAFF-BAFF receptor signaling inhibition on B cells was counterbalanced by the proatherogenic effect of the BAFF-TACI signaling inhibition on macrophages. In SLE patients, blood BAFF levels were associated with subclinical atherosclerosis (r = 0.26, P = 0.03). Anti-BAFF mAb treatment had a differential effect on the intima-media thickness progression in SLE patients depending on body mass index. Conclusion Depending on the balance between lipid- and B cell-induced proatherogenic conditions, anti-BAFF could be detrimental or beneficial, respectively, to atherosclerosis development in SLE.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据